Browse
Submit Data
Databases
API
Help

Dataset Information

6 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Clinical Trial of Camrelizumab Combined with Cetuximab and Chemotherapy Drugs to treat Ras Wild Colorectal Cancer

ABSTRACT: Interventions: 1:Camrelizumab, Cetuximab, and chemotherapeutics.;2:Camrelizumab, Cetuximab and chemotherapeutics. Primary outcome(s): ORR Study Design: Non randomized control

DISEASE(S): Ras Wild Colorectal Cancer

PROVIDER: 2688526 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Json Xml

Similar Datasets

A clinical study of microwave ablation combined with camrelizumab, cetuximab and chemotherapy in the treatment of RAS/BRAF wild-type microsatellite-stable metastatic colorectal cancer

Project description:Interventions: Test group:Camrelizumab + Cetuximab + Chemotherapy Primary outcome(s): the PFS rate of 12 months Study Design: Single arm

| 82248 | ecrin-mdr-crc

Single-arm phase II exploratory study of cetuximab combined with camrelizumab in RAS wild-type recurrent or distantly metastatic advanced colorectal cancer after failure of second-line standard therapy

Project description:Interventions: Experimental group:Cetuximab:500mg/m2,d1,q2w Camrelizumab:200mg, d1, q2w Primary outcome(s): Objective response rate Study Design: Single arm

| 85219 | ecrin-mdr-crc

Clinical study of Camrelizumab combined with Bevacizumab and DC-CIK in the treatment of advanced colorectal cancer

Project description:Interventions: single arm:camrelizumab, bevacizumab and DC-CIK Primary outcome(s): ORR Study Design: Single arm

| 2692527 | ecrin-mdr-crc

Molecular mechanisms and potential therapeutic drugs linking to cetuximab-induced reactions in human cells (HaCaT cells)

Project description:To obtain differentially expressed genes associated with cetuximab induced cytotoxicity we analyzed RNA samples using whole genome microarray expression profiling as a discovery platform to identify genes . Two kinds of RNA samples were extracted from HaCaT and HEK 293 cell; without cetuximab and incubation for 24 hours with 1.63μM (fixed maintenance dose) cetuximab.

2018-09-30 | GSE111885 | GEO

Molecular mechanisms and potential therapeutic drugs linking to cetuximab-induced reactions in human cells (HEK 293 cells)

2018-09-30 | GSE111886 | GEO

Molecular mechanisms and potential therapeutic drugs linking to cetuximab-resistance reactions in cancer cells

Project description:To obtain differentially expressed genes associated with cetuximab resistance mechanism, we analyzed RNA samples using whole genome microarray expression profiling as a discovery platform to identify genes. Two kinds of RNA samples were extracted from SAS, Sa3, and HSC-3 cells: control cells and cetuximab-resistant cells.

2018-12-01 | GSE114928 | GEO

Efficacy and safety of cetuximab plus FOLFIRI/FOLFOX combined with thalidomide in first-line treatment of RAS and BRAF wild-type stage IV left colorectal cancer

Project description:Interventions: Experimental group:cetuximab plus FOLFIRI/FOLFOX combined with thalidomide Primary outcome(s): Objective response rate, ORR Study Design: Single arm

| 86573 | ecrin-mdr-crc

Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer

Project description:The efficacy and safety of the use of Camrelizumab combined with Apatinib

| 2314620 | ecrin-mdr-crc

Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer

Project description:This study aimed to evaluate the efficacy and safety of camrelizumab combined with trastuzumab and chemotherapy in Patients with HER2-positive advanced colorectal cancer

| 2401102 | ecrin-mdr-crc

New drugs to treat tuberculosis.

Project description:Tuberculosis (TB) has been a leading cause of death for more than a century. While effective therapies exist, treatment is long and cumbersome. Tuberculosis control is complicated by the overlapping problems created by global inadequacy of public health infrastructures, the interaction of the TB and human immunodeficiency virus epidemics, and the emergence of drug-resistant TB. After a long period of neglect, there is now significant progress in development of TB diagnostics and therapeutics. Focusing on treatment for active TB, we review the new pathways to TB regimen development, and the new and repurposed anti-TB agents in clinical development.

| S-EPMC3370665 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data